V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10429154 | 10041561 | 1.72 | 66.85 | Disease modification (D) | 2019-03-21 | 2019-03-27 | Doxorubicin 75mg/m2 | 02 | Y | FLAIR TRIAL | 100197176 |
| 10429186 | 10041562 | 1.56 | 83.3 | Disease modification (D) | 2018-06-23 | 2018-06-23 | ANAGRELIDE | N | null | BORTEZOMIB + PANOBINOSTAT | 100345001 |
| 10429245 | 10041565 | 1.73 | 95.6 | Curative (C) | 2020-04-15 | 2020-04-15 | DA 3 + 10 | 01 | null | IDELALISIB + RITUXIMAB | 101686829 |
| 10429258 | 10041566 | 1.55 | 53.3 | null | 2021-08-01 | 2021-08-08 | Myeloma XV Trial | 02 | null | BORTEZOMIB + DARATUMUMAB | 101685079 |
| 10429259 | 10041567 | 1.78 | 60.9 | Palliative (P) | null | 2019-07-18 | Cisplatin + Etoposide (3 day) | 01 | N | METHOTREXATE | 101488142 |
| 10429308 | 10041569 | 1.73 | 84.9 | 03 | 2021-07-23 | 2021-09-07 | CYCLOPHOSPHAMIDE + DOXORUBICIN + PROCARBAZINE + VINCRISTINE | N | null | GEMCARBO | 101214474 |
| 10429313 | 10041570 | 1.63 | 91.8 | Neo-adjuvant (N) | 2021-02-28 | 2021-03-08 | Obinutuzumab + Venetoclax | 02 | N | LETROZOLE + PALBOCICLIB | 100516871 |
| 10429350 | 10041572 | 1.68 | 82.5 | Palliative (P) | 2021-10-17 | 2021-10-17 | Obinutuzumab +CVP | N | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100701874 |
| 10429360 | 10041573 | 1.75 | 101.3 | Palliative (P) | 2020-01-28 | 2020-02-16 | CAPECITABINE + CARBOPLATIN | N | null | GEMCARBO | 101389522 |
| 10429362 | 10041574 | 1.81 | 98 | Curative (C) | 2019-08-12 | 2019-08-30 | TIP | 02 | N | APALUTAMIDE | 101266179 |
| 10429392 | 10041575 | 1.64 | 78 | Palliative (P) | 2019-09-29 | 2019-10-08 | Radium 223 | 02 | N | VINCRISTINE | 100018351 |
| 10429398 | 10041576 | 1.58 | 89.9 | Curative (C) | 2019-11-08 | 2019-11-10 | Carboplatin+Fluorouracil 4 or 5 day | 02 | Y | AFATINIB | 101575272 |
| 10429476 | 10041577 | 1.68 | 54.5 | 03 | 2018-05-02 | 2018-05-02 | PARTNER Trial | N | N | VEDEX | 100699439 |
| 10429531 | 10041578 | null | 72 | Palliative (P) | 2019-12-16 | 2020-01-09 | Atezolizumab | 02 | null | CVD | 100069971 |
| 10429547 | 10041579 | 1.78 | 84.9 | Palliative (P) | 2018-10-15 | 2018-11-23 | EVEROLIMUS | 02 | N | AVELUMAB + AXITINIB | 101862473 |
| 10429579 | 10041580 | 1.74 | 57.2 | Curative (C) | 2019-11-29 | 2019-11-30 | EOX | 02 | N | TRASTUZUMAB | 101234113 |
| 10429607 | 10041581 | 1.82 | 62.5 | null | 2018-11-17 | 2018-12-05 | Oxaliplatin + Modified de Gramont | 02 | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100469914 |
| 10429639 | 10041582 | 1.46 | 80.3 | Disease modification (D) | null | 2019-10-04 | Vemurafenib | 01 | N | CHLVPP | 100996160 |
| 10429831 | 10041586 | 1.68 | 73.1 | null | 2020-09-09 | 2020-09-20 | MYELOMA XI TRIAL | 02 | null | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100080587 |
| 10429877 | 10041587 | 1.72 | 83.2 | Curative (C) | 2019-10-30 | 2019-11-06 | Irinotecan 14day | N | N | STAMPEDE TRIAL | 101260661 |
| 10429983 | 10041591 | 1.81 | 64.4 | 03 | 2020-01-13 | 2020-01-16 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | null | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 100827463 |
| 10430003 | 10041592 | 1.76 | null | Disease modification (D) | null | 2018-10-01 | Bendamustine + Obinutuzumab | N | N | BENDAMUSTINE | 100282659 |
| 10430229 | 10041597 | 1.71 | 76.2 | Curative (C) | null | 2019-01-20 | Apalutamide | null | N | CYCLOPHOSPHAMIDE HIGH DOSE | 100505190 |
| 10430234 | 10041598 | 0 | null | Palliative (P) | 2018-09-01 | 2018-09-15 | null | 02 | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 100028405 |
| 10430304 | 10041599 | 1.69 | 60 | Curative (C) | 2019-09-21 | 2019-10-12 | Obinutuzumab + Venetoclax | 02 | null | LUTETIUM-177 | 101599562 |
| 10430367 | 10041601 | 1.79 | 73.1 | null | 2017-09-30 | 2017-10-15 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 1 | N | CARBOPLATIN + DOCETAXEL | 100926273 |
| 10430429 | 10041603 | 1.7 | 78.9 | Disease modification (D) | null | 2020-03-28 | ICE-R | 01 | N | ANAGRELIDE | 100305062 |
| 10430513 | 10041604 | 1.71 | 73 | null | 2018-08-20 | 2018-08-25 | Obinutuzumab +CVP | 02 | N | INTERFERON ALFA | 101149832 |
| 10430640 | 10041606 | 1.63 | 0 | Palliative (P) | 2019-07-27 | 2019-08-10 | Bortezomib + Daratumumab | N | N | GEMCARBO | 100014383 |
| 10430766 | 10041608 | 1.73 | 58 | null | 2017-06-14 | 2017-06-14 | Irinotecan + Modified De Gramont | 02 | null | DABRAFENIB | 101304162 |
| 10430795 | 10041609 | null | 58 | Curative (C) | 2019-02-05 | 2019-03-02 | Cyclophosphamide oral | 02 | null | EVEROLIMUS | 101863415 |
| 10430797 | 10041610 | null | 51.9 | Curative (C) | 2019-09-28 | 2019-09-28 | null | 02 | null | CAPECITABINE + CARBOPLATIN | 100572645 |
| 10430845 | 10041612 | 1.55 | 69 | Neo-adjuvant (N) | 2018-01-17 | 2018-01-17 | Obinutuzumab +CVP | Y | N | OSIMERTINIB | 101209998 |
| 10430927 | 10041614 | 1.8 | 110 | Palliative (P) | 2019-04-29 | 2019-05-06 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101607791 |
| 10430929 | 10041615 | 1.8 | 68.5 | Disease modification (D) | 2021-03-05 | 2021-03-06 | Ixazomib + Lenalidomide | N | null | ASCIMINIB | 100240285 |
| 10430966 | 10041620 | 1.58 | 87.9 | Disease modification (D) | 2020-05-15 | 2020-06-07 | AZACITIDINE + VENETOCLAX | 02 | null | CAPECITABINE + CARBOPLATIN | 101638547 |
| 10431031 | 10041621 | 1.72 | 54.1 | 03 | 2018-10-15 | 2018-10-20 | Cetuximab + FOLFIRI cycle1 | 02 | N | FEC + DOCETAXEL + TRASTUZUMAB | 100018136 |
| 10431072 | 10041623 | 1.61 | 122 | Not known (9) | 2020-08-05 | 2020-08-05 | MPV (cycle 1-4) | N | null | GEMCITABINE + NAB-PACLITAXEL | 100546999 |
| 10431192 | 10041625 | 0 | null | 03 | 2019-06-09 | 2019-06-23 | TCH (21 day Trastuzumab) Loading | 02 | null | LETROZOLE + PALBOCICLIB | 101121873 |
| 10431383 | 10041629 | 1.55 | 83 | Palliative (P) | null | 2017-10-15 | Binimetinib + Encorafenib | 02 | N | ETOPOSIDE | 100178805 |
| 10431396 | 10041630 | 0 | 110 | Palliative (P) | 2019-09-10 | 2019-09-10 | MYELOMA XIV TRIAL | N | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101036371 |
| 10431408 | 10041631 | null | 81 | Curative (C) | 2019-12-06 | 2019-12-20 | Fulvestrant + Palbociclib | 02 | null | ICON8B TRIAL | 100352002 |
| 10431514 | 10041633 | null | null | Curative (C) | 2019-06-13 | 2019-06-21 | Binimetinib + Encorafenib | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100349527 |
| 10431550 | 10041634 | 1.72 | 102.1 | Palliative (P) | 2019-06-15 | 2019-06-17 | Bortezomib + Daratumumab | 02 | Y | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101823083 |
| 10431575 | 10041635 | 1.72 | 63 | Adjuvant (A) | null | 2016-08-09 | Nilotinib | N | Y | RITUXIMAB + VENETOCLAX | 101757033 |
| 10431586 | 10041636 | 1.82 | 59.4 | Adjuvant (A) | 2017-06-05 | 2017-06-06 | ECX | N | N | FLAG + IDARUBICIN | 100908116 |
| 10431592 | 10041637 | 1.69 | null | Disease modification (D) | 2016-02-04 | 2016-02-13 | Everolimus 10mg | 02 | N | STAMPEDE TRIAL | 101670427 |
| 10431670 | 10041638 | 1.7 | 69.45 | 03 | 2019-11-27 | 2019-12-14 | MATRIX (lymphoma) | 02 | N | TRABECTEDIN | 100044597 |
| 10431812 | 10041639 | 1.6 | 0 | Palliative (P) | null | 2018-06-23 | LANREOTIDE | 02 | N | TRASTUZUMAB EMTANSINE | 100921645 |
| 10431884 | 10041642 | 1.83 | null | Adjuvant (A) | 2016-10-20 | 2016-10-21 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100540443 |